100.67 USD
+1.9 (+1.92%)
INCY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. INCY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on INCY. With these ratings, INCY could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
INCY had positive earnings in the past year.
INCY had a positive operating cash flow in the past year.
Of the past 5 years INCY 4 years were profitable.
INCY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
INCY has a better Return On Assets (18.78%) than 96.79% of its industry peers.
INCY's Return On Equity of 25.55% is amongst the best of the industry. INCY outperforms 96.98% of its industry peers.
INCY has a better Return On Invested Capital (19.88%) than 97.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for INCY is significantly below the industry average of 18.28%.
The 3 year average ROIC (7.24%) for INCY is below the current ROIC(19.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROIC | 19.88% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
INCY has a Profit Margin of 24.69%. This is amongst the best in the industry. INCY outperforms 94.72% of its industry peers.
In the last couple of years the Profit Margin of INCY has declined.
Looking at the Operating Margin, with a value of 26.10%, INCY belongs to the top of the industry, outperforming 95.85% of the companies in the same industry.
In the last couple of years the Operating Margin of INCY has declined.
With an excellent Gross Margin value of 93.47%, INCY belongs to the best of the industry, outperforming 94.53% of the companies in the same industry.
In the last couple of years the Gross Margin of INCY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INCY is creating value.
The number of shares outstanding for INCY has been reduced compared to 1 year ago.
The number of shares outstanding for INCY has been reduced compared to 5 years ago.
Compared to 1 year ago, INCY has a worse debt to assets ratio.
2.2 Solvency
INCY has an Altman-Z score of 8.88. This indicates that INCY is financially healthy and has little risk of bankruptcy at the moment.
INCY has a better Altman-Z score (8.88) than 80.94% of its industry peers.
INCY has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.03, INCY belongs to the top of the industry, outperforming 96.42% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
INCY has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: INCY outperforms 46.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 8.88 |
ROIC/WACC2.26
WACC8.81%
2.3 Liquidity
INCY has a Current Ratio of 3.20. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
INCY has a Current ratio of 3.20. This is in the lower half of the industry: INCY underperforms 61.70% of its industry peers.
A Quick Ratio of 3.13 indicates that INCY has no problem at all paying its short term obligations.
With a Quick ratio value of 3.13, INCY perfoms like the industry average, outperforming 40.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 575.79% over the past year.
The earnings per share for INCY have been decreasing by -14.21% on average. This is quite bad
INCY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.09%.
Measured over the past years, INCY shows a quite strong growth in Revenue. The Revenue has been growing by 14.46% on average per year.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
3.2 Future
Based on estimates for the next years, INCY will show a very strong growth in Earnings Per Share. The EPS will grow by 28.45% on average per year.
INCY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.17% yearly.
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y28.45%
Revenue Next Year18.26%
Revenue Next 2Y14.47%
Revenue Next 3Y12.87%
Revenue Next 5Y1.17%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
INCY is valuated correctly with a Price/Earnings ratio of 15.68.
Compared to the rest of the industry, the Price/Earnings ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 95.47% of the companies listed in the same industry.
INCY's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.51.
A Price/Forward Earnings ratio of 12.51 indicates a correct valuation of INCY.
97.36% of the companies in the same industry are more expensive than INCY, based on the Price/Forward Earnings ratio.
INCY's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.68 | ||
| Fwd PE | 12.51 |
4.2 Price Multiples
INCY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INCY is cheaper than 96.23% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 96.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.51 | ||
| EV/EBITDA | 11.88 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of INCY may justify a higher PE ratio.
A more expensive valuation may be justified as INCY's earnings are expected to grow with 91.00% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y146.91%
EPS Next 3Y91%
5. Dividend
5.1 Amount
INCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:INCY (1/2/2026, 3:35:10 PM)
100.67
+1.9 (+1.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.03%
Inst Owner Change1.22%
Ins Owners1.74%
Ins Owner Change-9.87%
Market Cap19.76B
Revenue(TTM)4.81B
Net Income(TTM)1.19B
Analysts75
Price Target101.7 (1.02%)
Short Float %5.6%
Short Ratio4.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)7.59%
PT rev (3m)20.25%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)7.46%
EPS NY rev (1m)0.19%
EPS NY rev (3m)10.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.61%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)2.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.68 | ||
| Fwd PE | 12.51 | ||
| P/S | 4.11 | ||
| P/FCF | 16.51 | ||
| P/OCF | 15.79 | ||
| P/B | 4.25 | ||
| P/tB | 4.52 | ||
| EV/EBITDA | 11.88 |
EPS(TTM)6.42
EY6.38%
EPS(NY)8.05
Fwd EY7.99%
FCF(TTM)6.1
FCFY6.06%
OCF(TTM)6.37
OCFY6.33%
SpS24.52
BVpS23.69
TBVpS22.29
PEG (NY)0.04
PEG (5Y)N/A
Graham Number58.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROCE | 25.17% | ||
| ROIC | 19.88% | ||
| ROICexc | 48.14% | ||
| ROICexgc | 55.55% | ||
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% | ||
| FCFM | 24.87% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 59.08% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.81% | ||
| Profit Quality | 100.71% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | 8.88 |
F-Score7
WACC8.81%
ROIC/WACC2.26
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y428.71%
EPS Next 2Y146.91%
EPS Next 3Y91%
EPS Next 5Y28.45%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year18.26%
Revenue Next 2Y14.47%
Revenue Next 3Y12.87%
Revenue Next 5Y1.17%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year366.76%
EBIT Next 3Y85.61%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%
INCYTE CORP / INCY FAQ
What is the fundamental rating for INCY stock?
ChartMill assigns a fundamental rating of 7 / 10 to INCY.
What is the valuation status of INCYTE CORP (INCY) stock?
ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.
How profitable is INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a profitability rating of 7 / 10.
How financially healthy is INCYTE CORP?
The financial health rating of INCYTE CORP (INCY) is 8 / 10.
Can you provide the expected EPS growth for INCY stock?
The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 428.71% in the next year.